Dmitry Lyalin

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang et al. · Clinical Cancer Research · 2014 · 120 citations · Full text

Medicine, Oncology, Pharmacology +16

The <i>twisted</i> Gene Encodes Drosophila Protein <i>O-</i>Mannosyltransferase 2 and Genetically Interacts With the <i>rotated abdomen</i> Gene Encoding Drosophila Protein <i>O-</i>Mannosyltransferase 1

Dmitry Lyalin, Kate Koles, Sigrid D. Roosendaal et al. · Genetics · 2005 · 50 citations · Full text

Life Sciences, Developmental Biology, Genetics +8

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

Hernán Carol, Richard Görlick, E. Anders Kolb et al. · Pediatric Blood & Cancer · 2013 · 47 citations · Full text

Medicine, Oncology, Pharmacology +9

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program

Edward F. Attiyeh, John M. Maris, Richard B. Lock et al. · Pediatric Blood & Cancer · 2015 · 37 citations · Full text

Medicine, Oncology, Pharmacology +13

Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program

Min H. Kang, C. Patrick Reynolds, E. Anders Kolb et al. · Pediatric Blood & Cancer · 2016 · 35 citations · Full text

Medicine, Oncology, Pharmacology +13